Freeline Therapeutics Gene Therapy

Gene Therapy for Hemophilia B can replace lifelong need for factor IX injections

Freeline Therapeutics has advanced a new gene therapy that can potentially replace the need for lifelong factor IX injections in patients with Hemophilia B. This could emerge as a game changer in the management of Hemophilia B, a hereditary bleeding disorder. The absence of factor IX which is a naturally produced protein known for its…